Identification of novel NK1/NK3 dual antagonists for the potential treatment of schizophrenia

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 22, 2011, Pages 6899-6904

  Catalani, Maria Pia ^a,c   Alvaro, Giuseppe ^a   Bernasconi, Giovanni ^a   Bettini, Ezio ^a   Bromidge, Steven M ^b   Heer, Jag ^b   Tedesco, Giovanna ^a   Tommasi, Simona ^a  

^a GSK   (Italy)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Aptuit Inc   (United States)

Author keywords

Antipsychotic; Neurokinin receptors; NK1 NK 3 receptor antagonist; Schizophrenia

Indexed keywords

CARBONYL DERIVATIVE; HYDROXYL GROUP; LACTAM DERIVATIVE; METHYL GROUP; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 3 RECEPTOR; NEUROKININ 3 RECEPTOR ANTAGONIST; LACTAM; NEUROLEPTIC AGENT;

ARTICLE; DRUG IDENTIFICATION; DRUG SYNTHESIS; IN VITRO STUDY; SCHIZOPHRENIA; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; HUMAN; METABOLISM; STRUCTURE ACTIVITY RELATION;

ANTIPSYCHOTIC AGENTS; HUMANS; LACTAMS; MODELS, MOLECULAR; RECEPTORS, NEUROKININ-1; RECEPTORS, NEUROKININ-3; SCHIZOPHRENIA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80054738939     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.07.116     Document Type: Article

References (30)

1. C. Severini, G. Improta, G. Falconieri-Erspamer, S. Salvadori, and V. Erspamer Pharmacol. Rev. 54 2002 285
2. J.N. Pennefather, A. Lecci, M.L. Candenas, E. Patak, F.M. Pinto, and C.A. Maggi Life Sci. 74 2004 1445
3. K. Ebner, S.B. Sartori, and N. Singewald Curr. Pharm. Des. 15 2009 1647
4. L.A. Chahl Curr. Drug Targets 7 2006 993
5. G. Alvaro, and R. Di Fabio Curr. Opin. Drug Dis. Dev. 10 2007 613
6. I. Herpfer, and K. Lieb CNS Drugs 19 2005 275
7. H.Y. Meltzer, L. Arvanitis, D. Bauer, and W. Rein Am. J. Psychiatry 161 2004 975
8. L.A. Dawson, and P.W. Smith Curr. Pharm. Des. 16 2010 344
9. (a) Hoffmann, T.; Koblet, A.; Peters, J.U.; Schnider, P.; Sleight, A.; Stadler, H. PCT Int. Appl.,WO2005002577, 2005;
10. (b) Bissantz, C.; Hoffmann, T.; Jablonski, P.; Knust, H.; Nettekoven, M.; Ratni, H.; Wu, X. PCT Int. Appl., WO2008128891, 2008.
11. Schnider, P. PCT Int. Appl., WO2006013050, 2006.
12. Alvaro, G.; Andreotti, D.; Belvedere, S.; Di Fabio, R.; Falchi, A.; Giovannini, R. PCT Int. Appl.,WO2007028654, 2007.
13. J.U. Peters, T. Hoffmann, P. Schnider, H. Stadler, A. Koblet, A. Alker, S.M. Poli, T.M. Ballard, W. Spooren, L. Steward, and A.J. Sleight Bioorg. Med. Chem. Lett. 20 2010 3405
14. H. Ratni, T.M. Ballard, C. Bissants, T. Hoffmann, P. Jablonski, F. Knoflach, H. Knust, P. Malherbe, M. Nettekoven, A. Patiny-Adam, C. Riemer, M. Schmitt, and W. Spooren Bioorg. Med. Chem. Lett. 20 2010 6735
15. Structures were modeled within the Maestro [A] modeling environment. Conformational analyses were carried out with BatchMin [B] using the following parameters: 1000 steps/rotatable bond, OPLS-2005 FF, implicit water model of solvation, 10000 minimisation steps with PRCG, relative energy window for the minimized conformers within 3 kcal/mol. On the left hand side of the compounds, H-bond acceptor (A2, A3) and donor (D4) pharmacophore features were mapped using the Phase [C] module within Maestro. [A] Maestro V8.5.111 (Schrodinger LLC). [B] BatchMinV9.6 (Schrodinger LLC). [C] Phase V3.0.110 (Schrodinger LLC).
16. Bromidge, S.M.; Catalani, M.P.; Heer J.P.; Smethurst, C. A. P.; Tommasi, S. PCT Int. Appl, WO 2011054773, 2011.
17. Jones, P.; Pryde, C.; Fran, T.-D. PCT Int. Appl., WO2007093901, 2007.
18. B.K. Chan, and M.A. Cinfolini J. Org. Chem. 72 2007 8489
19. B. Metten, M. Kostermans, G. Van Baelen, M. Smet, and W. Dehaen Tetrahedron 62 2006 6018
20. F. Felluga, M. Fermeglia, M. Ferrone, G. Pitacco, S. Pricl, and E. Valentin Helv. Chim. Acta 8 2002 4046
21. The four stereoisomers obtained by reduction of 7 were separated by chiral SFC. Preparative chromatography conditions: [Column: ChiralPak AD-H (25 × 2.1 cm); Modifier: 12% (EtOH + 0.1% isopropylamine) 12%, 15% after third peak; Flow rate 50.0 ml/min; UV detection 220 nM; Loop 500 μl]. Injection of 10 mg in the modifier to give in order to elution: 8a, 9a, 8b, and 9b.
22. L. Yan, R. Budhu, P. Huo, C.L. Lynch, J.J. Hale, S.G. Mills, R. Hajdu, C.A. Keohane, M.J. Rosenbach, J.M. Milligan, G.-J. Shei, G. Chrebet, J. Bergstrom, D. Card, and S.M. Mandela Bioorg. Med. Chem Lett. 16 2006 3564
23. Preparative chromatographic conditions: Column: ChiralPak AD-H (25 × 0.46 cm); Mobile phase: n-hexane/EtOH 65/35% v/v; Flow rate: 0.8 ml/min. DAD:210-340 nM to give according to the order of elution 15a (anti enantiomer 1) and 15b (anti enantiomer 2).
24. Compound 19 was separated using the following chiral HPLC preparative conditions: Column: Chiralpak IC (20 mm × 250mm, 5 μm); Heptane: IPA 70:30 v/v pump-mixed; Flow rate = 17.0 ml/min; UV absorbance 215 nM; Autosampler injection (500 μl of 140.0 mg/ml sample in DCM/MeOH 8:2 on column); isocratic run time = 50.0 min.
25. R.B. Silverman, and S.M. Nanavati J. Med. Chem. 33 1990 931
26. Compounds 21a and 22b were isolated (in order of elution) from the mixture of four diasteroisomers using the following preparative chiral HPLC conditions: Column: Chiralpak IA (20 mm × 250mm, 5 μm); Heptane: Absolute Ethanol 90:10 v/v pump-mixed; Flow rate = 17.0 ml/min; UV Absorbance 215 nM; Autosampler injection (900 μl of 95.0 mg/ml sample in DCM:MeOH 8:2 on column); isocratic run time = 50.0 min. The mixture of 21b and 22a was subsequently separated (in order of elution) according the following chiral HPLC condition: Column: Chiralpak IC (20 mm × 250mm, 5 μm); Heptane: IPA 70:30 v/v pump-mixed; Flow rate = 17.0 ml/min; UV Absorbance 215 nM; Autosampler injection (900 μl of 95.0 mg/ml sample in DCM/MeOH 8:2 on column); isocratic run time = 60.0 min.
27. i) values from the pIC50 values.
28. Different categories of receptor antagonists have been described. Some antagonists produce parallel rightward shifts of the agonist concentration-response curve, without affecting the maximal response. These are classified as surmountable antagonists (Gaddum, J.H.; Hameed, K.A.; Hathway, D.E.; Stephens, F.F. Q. J. Exp. Physiol. 1955, 40, 49). Insurmountable antagonists are able to depress the maximal response.
29. E. Lindström, B. Von Mentzer, I. Phlman, I. Ahlstedt, A. Uvebrant, E. Kristensson, R. Martinsson, A. Novén, J. De Verdier, and G.J. Vauquelin Pharmacol. Exp. Ther. 322 2007 1286
30. max in the presence of two selected test compound concentrations is shown in Tables 2 and 3.